Just Who Is Clay Siegall & What Does He Do?

If you’re not too familiar with cancer research then you probably won’t recognize the name in this article, but this article is a great place to educate you on a very special individual. This individual has changed the game when it comes to the fight against cancer and his organization firmly sits at the top of the apex thanks to it’s great products and services. Clay Siegall is the name in question and Seattle Genetics is the organization he represents. Clay Siegall is by far one of the biggest names in cancer research and has been for some time now. He has led this valiant fight for many years while working with many high profile organizations such as Bristol Myers Squibb, The National Institute of Health, as well as The National Cancer Institute.


Clay Siegall has many titles thanks to his broad educational background. He’s known to be a scientist, philanthropist, guest speaker, fund raiser, and doctor. This brilliant minded individual attended the University of Maryland where obtained a (BS) in Zoology. The good doctor also earned a Ph.D in Genetics from the prestigious George Washington University. With all of these accomplishments you would think that he would be a household name, but unfortunately that isn’t the case. Dr. Siegall isn’t in it for fame, he’s in it to save lives and his company Seattle Genetics produces some of the best antibody based therapies in the business. These breakthrough therapies are known as (ADCs) aka Antibody Drug Conjugates. They specifically target cancerous cells within the body and attacks them with cell killing agents. This method is much more efficient as it spares all non-targeted cells within the body which cuts down on nasty side effects.


HeraldNet News reported that Seattle Genetics will be hiring at least 200 more employees in the near future in part by it’s huge growth. This will bring the company’s total up to around 1,100 in all. Dr. Siegall is the man in charge and will continue to see this progression through to the end.